Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®

The drug that is under investigation during this study is RhuDex® and is expected to be used as an oral treatment for rheumatoid arthritis. Normal stomach juices contain acid and previous studies have shown that this acidity reduces the solubility and therefore the absorption of RhuDex®. Administering the alkaline buffer meglumine with RhuDex® has shown to increase the solubility of RhuDex® by decreasing the stomach acidity. The purposes of this study are to determine: * the optimum level of meglumine which is required to achieve the best uptake of RhuDex® from the stomach into the blood * to determine the concentration of RhuDex® in the blood in the presence of the optimum level of meglumine * to investigate further the safety and tolerability of RhuDex®. The study will be conducted in healthy male volunteers.